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ABSTRACT
Drug-induced hypersensitivity syndrome (DIHS; also known as drug reaction 
with eosinophilia and systemic symptoms [DRESS]) is a life-threatening 
condition first described by Chaiken et al. in 1950. It is characterized by extensive 
mucocutaneous rash; fever; lymphadenopathy; hepatitis; hematological 
abnormalities; damage to several organs such as kidney, heart, lungs, and 
pancreas; and possible reactivation of human herpesvirus-6 (HHV-6) or other 
herpes virus. Rare and severe cases may present hepatic necrosis, and about 
15% of them result in death or liver transplantation. A hallmark of this syndrome 
is the late onset of symptoms after the drug exposure. The most common 
culprit drugs are the aromatic anticonvulsants (in almost 30% of the cases) 
and the antibiotics (which in some series represent 20% of the cases). The 
authors report a case of a 41-year-old female who presented to the emergency 
department with erythroderma, acute hepatitis, acute pancreatitis and acute 
renal failure, and was then treated with corticosteroid after the diagnosis of 
DIHS/DRESS. A specific culprit drug could not confidently be determined due 
to the presence of multiple drugs used by the patient. The clinical and laboratory 
outcome was apparently satisfactory, but unexpectedly, on the sixth day of 
hospitalization, the patient complained of nonspecific malaise, drowsiness, 
which progressed in a few hours with signs and symptoms of hepatic failure, 
refractory shock, and death. The autopsy findings showed submassive hepatic 
necrosis, and the immediate cause of death was attributed to hepatic failure.
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CASE REPORT
A 41-year-old female patient, previously 
diagnosed with rheumatoid arthritis, sought the 
emergency department complaining of pruritus 
and cutaneous eruption associated with anorexia, 
fever, and myalgia. Three days after the onset of 
symptoms, she referred epigastric pain, nausea, 
vomiting, jaundice, choluria, and her skin started 
diffuse scaling. She referred urinary tract infection, 
which was treated with ciprofloxacin until two weeks 
before the initial symptomatology. On this occasion, 
she also used scopolamine, dipyrone, and diclofenac. 
She had been taking prednisone 15 mg/day for the 
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The patient started receiving prednisone 
0.5 mg/kg/day and showed a slight clinical improvement 
until the sixth hospitalization day when she started 
presenting nonspecific malaise, somnolence, 
tachycardia, and hypotension. Laboratory tests showed 
metabolic acidosis and deteriorating liver function. 
The patient was referred to the intensive care unit 
but died in 12 hours because of refractory shock.
Retrospectively, in a frozen stored serum 
sample, serology was positive for immunoglobulin G 
(IgG) and negative for IgM for cytomegalovirus and 
Epstein-Bar virus. Human herpes virus-6 (HHV-6) 
serology, studied by indirect immunofluorescence, 
was positive for IgG and negative for IgM. The 
immunoglobulin dosage was within the normal range.
AUTOPSY FINDINGS
External examination showed jaundice and 
diffuse cutaneous desquamation on the face, trunk, 
and limbs (Figures 1A, B). Skin microscopy showed 
dermatitis with scales formation and microscopic skin 
changes suggestive of drug-induced hypersensitivity 
reaction in an organization phase. Keratinocytes 
apoptosis, mild edema of the superficial dermis, and 
areas of dermal-epidermal cleavage characterized 
the microscopy of the skin (Figure 1C).
Lymph nodes examination showed lymphoid 
depletion without eosinophilic infiltration (Figure 1D).
last 3 months after methotrexate withdrawal. She 
denied alcohol consumption, smoking, or recent 
travel. Physical examination showed a well-looking 
patient, icteric, hydrated, and febrile. Blood pressure 
was 80/50 mmHg; pulse rate was 88 regular beats per 
minute. Dermatological examination showed a diffuse 
morbilliform exanthematous rash with desquamation 
compromising face, trunk, abdomen and upper limbs 
(more than 50% of the body surface). Her face and 
periorbital area were edematous, and the oral mucous 
membranes were slightly involved. The liver was 
tender and enlarged, palpable until 4 cm below the 
right costal margin. Lungs and cardiac examination 
were unremarkable. The initial laboratory work-up is 
shown in Table 1.
Urinalysis sowed proteinuria, occult blood, 
21,000 leukocytes/mm3 and 10,000 erythrocytes/mm3. 
Urine culture was negative. Upper abdominal 
ultrasonography (US) showed an enlarged liver 
and spleen, slightly distended gall bladder with no 
calculi images within the biliary system. Abdominal 
computerized tomography (CT) also showed the 
presence of lymphadenomegaly in the aortic and iliac 
chains, with lymph nodes measuring up to 2.2 cm, 
besides free liquid in the pelvis. Hepatitis A, B, and C 
and HIV serologies were all negative. Blood cultures 
were negative for all 6 samples collected.
The analysis of the laboratory tests allowed 
the conclusion of hepatic, kidney, and pancreatic 
involvement. Total blood cell count was characterized 
by leukocytosis, with lymphopenia and monocytosis. 
These results pointed towards the diagnosis of drug-
induced hypersensitivity syndrome (DIHS).
Table 1 – Initial laboratory examination work-up
Exam Result RV Exam Result RV
Hemoglobin 13.6 12.3-15.3 g/dL Sodium 130 136-146 mEq/L
Hematocrit 41.6 36.0-45.0% Potassium 3.9 3.5-5.0 mEq/L
Leukocytes 15,800 4.4-11.3 × 103/mm3 AST 345 10-31 U/L
Bands 0 1-5% ALT 425 9-36 U/L
Segmented 84 46-75% AP 1372 10-100 U/L
Eosinophil 0 1-4% γGT 1593 2-30 U/L
Basophil 0 0-2.5% Total bil. 21.3 0.3-1.2 mg/dL
Lymphocyte 5 18-40% Amylase 781 20-104 U/L
Monocyte 10 2-9% Lipase 918 < 60 U/L
Platelet 326 150-400 x 103/mm3 INR 1.11 1
Creatinine 2.2 0.4 -1.3 mg/dL Fibrinogen 573 175-400 mg/dL
Urea 154 10-50 mg/dL Triglycerides 315 <150 mg/dL
Ionized Ca+ 1.06 1.15 -1.35 Mmol/L Ferritin 1650 22-322 ng/mL
ALT = alanine aminotransferase; AP = Alkalline phosphatase; AST = aspartate aminotransferase; γGT = gamma-glutamyl transferase; 
INR = international normalization ratio; RV = reference value; Total bil = total bilirubins.
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The abdominal cavity showed the presence of 
700 mL of limpid and yellowish ascites. The viscera 
and fat tissue were diffusely stained by a yellow–
gold color, due to bile impregnation. The pancreas 
showed slight edema weighing 86 g (reference value 
[RV] = 110 g).
Over the organ, on parenchymal surface cuts, 
as well in the peripancreatic tissue, numerous foci 
of fat necrosis were found (Figures 3A, B). These 
Gross examination of the thoracic cavity 
disclosed congestion in both lungs. The myocardium 
showed tiny, yellowish and hardened consistency 
lesions (Figure 2A), which, on microscopy, 
corresponded to multiple foci of dystrophic calcification 
(Figure 2B) and areas of myocardial cell injury in 
organization (Figure 2C). These histological findings 
could represent toxic myocardial cells injury in a 
healing phase.
Figure 2 – A - Gross examination of the heart showing the presence of yellowish nodules (arrow); 
B - Photomicrography (H&E) of the myocardium showing multiple foci of dystrophic calcification; 
C - Photomicrography (H&E) of the myocardium showing areas of myocardial cell injury in organization.
Figure 1 – A and B - Gross examination of the body showing diffuse desquamation of the skin; 
C - Photomicrography (H&E) of the skin showing hyperkeratosis and flaking surface (long arrow) and multiple 
figures of keratinocyte apoptosis (small arrows); D - Photomicrography (H&E) of the lymph node showing 
lymphocyte depletion.
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DISCUSSION
DIHS, also known as drug reaction with 
eosinophilia and systemic symptoms (DRESS), is 
a life-threatening condition, which, in its complete 
form, is characterized by mucocutaneous rash, fever, 
lymphadenopathy, hepatitis, hematologic abnormalities, 
and damage to several organs such as kidney, heart, 
lungs, and pancreas.1 There is a trend to consider 
DIHS as the precise denomination for this syndrome. 
A hallmark of this syndrome is its late onset after the 
culprit drug exposure, unlike other drug reactions, 
which occur earlier after drug exposure, like the acute 
generalized erythematous pustulosis and Stevens-
Johnson syndrome/toxic epidermal necrolysis.2 This 
latency is fairly variable in the literature, described as 
being between 2 weeks and 3 months.1-3,4 Um et al.5 
reported 6 cases in a series of 38 patients, and 
Ang et al. reported 3 cases in a series of 27,6 where 
this latency period was less than 1 week. This small 
latency was correlated to antibiotics and NSAIDs. 
The syndrome may develop after the very first use 
of the drug and after its re-administration.1
findings confirmed the diagnosis of acute edematous 
pancreatitis on microscopy (Figures 3C, D).
The liver had a yellowish color, was 
of soft consistency, and weighed 1735 g (RV 
range = 1140-1450 g). The hepatic cut (Figure 4A) 
surface showed multiple bleeding points on the 
topography of the center-lobular hepatic vein, which 
was represented by extensive areas of necrosis and 
loss of the trabeculation on microscopic examination 
(Figures 4B-D).
The spleen was enlarged and congested, 
weighing of 549 g (RV = 112 g) showing acute splenitis 
(Figure 5A). Gross examination detected wedge areas 
of yellowish and soft consistency tissue (Figure 5B) 
that on microscopy corresponded to ischemic necrosis 
(Figure 5C). Additional findings included generalized 
visceral congestion; moderate esophagitis; gastritis; 
small mucosal bleeding points scattered in the cecum 
and ascending colon; uterine fibroids and corpus 
luteum hemorrhagic cysts in the ovary; and lipid 
deposition in the abdominal aorta. Remaining organs 
and tissues showed no significant alterations on gross 
and microscopic examination.
Figure 3 – A - Gross examination of the pancreas showing acute edematous pancreatitis with foci of 
fat necrosis on the surface of the organ (arrow) and in the cut surface of the parenchyma in B; C and 
D - Photomicrography (H&E) of the pancreas depicting pancreatic and peripancreatic fat necrosis.
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Figure 4 – A - Gross examination of the hepatic cut surface showing yellowish and hemorrhagic areas; 
B and C - Photomicrography (H&E) of the liver showing hepatic necrosis; D - Photomicrography of the liver 
(immunohistochemical staining for reticulin) showing the loss of the normal liver parenchyma trabeculation.
Figure 5 – A - Gross appearance of the enlarged spleen; B - Gross examination of the splenic cut surface 
showing acute splenitis, and ischemic wedge yellowish areas; C - Photomicrography (H&E) of the spleen 
showing ischemic necrosis.
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First described by Chaiken et al. in 1950,7 
DIHS is an unpredictable reaction with an incidence 
ranging from 1 in 1000 to 1 in 10,000 patients.5,8,9 
It occurs more frequently in adults, has no gender 
predominance1, and is not related to dose or serum 
concentration of the offending drug.10 Mortality is 
observed in 10-20% of the cases, especially those 
related to advanced age, renal impairment, and severe 
hepatic injury.1,11
The exact mechanism by which the drug 
triggers the syndrome remains to be fully determined. 
Pathogenic data are more consistent with aromatic 
anticonvulsants as culprit drugs, but there is a trend 
to accept the same mechanisms when other dugs 
are involved. The ethiopathopenesis of DIHS/DRESS 
comprises: a) deficiency of the epoxide hydroxylase 
enzyme that detoxifies drug metabolites (in this case, 
the accumulation of arene oxides promotes direct 
cellular toxicity and/or triggers an immune response); 
b) reactivation of herpes virus family; and c) genetic 
predisposition (abnormal detoxification of some drugs 
is thought to be inherited in autosomic co-dominant 
fashion12 and familial cases have been reported 
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has already been reported in the literature presenting 
similar clinical picture.23 Ciprofloxacin has been also 
recognized as a drug capable of causing hepatic 
injury. A study of cases from Drug-Induced Liver 
Injury Network (DILIN) from September 2004 to 
January 2010 found 12 cases (out of 679), related 
to fluoroquinolones hepatotoxicity. In this study,24 
the average time between the drug and the onset 
of symptoms was 4 days (range 1-39 days); one of 
these cases died because of acute hepatic failure. 
Ciprofloxacin was the drug in 6 of these cases.24
Fever as high as 38-40 °C is the most common 
symptom occurring in 90-100%25 of cases followed 
in frequency (90%)25 by involvement of the skin, 
which is characterized by a morbilliform rash, which 
is indistinguishable, in most cases, from other drug 
reactions. The face, upper trunk, and upper extremities 
are initially affected, with subsequent progression to 
the lower limbs. Swelling of the face, with marked 
periorbital involvement may be a diagnostic clue 
and is present in 25% of cases.25 The maculopapular 
eruption later becomes infiltrated, and vesicles are 
infrequent. Over time, the rash becomes purplish and 
ends with scaling.1,26 Another form of presentation is 
as exfoliative dermatitis, also associated with mucosal 
involvement.27 A skin biopsy does not establish the 
diagnosis but can assist in its confirmation, showing 
lymphocytic infiltration of the papillary dermis that may 
contain eosinophils and perivascular inflammatory 
infiltrate.6,28 The patient of this case report presented 
high grade fever from the onset until the end. Her 
cutaneous involvement was represented by generalized 
erythema (exanthematous rash) with scaling and 
facial edema.
Lymphadenopathy may be localized or 
generalized and occurs in 50-75% of the cases.5,25 The 
lymph nodes may present a benign pattern of lymphoid 
hyperplasia or a standard pseudolymphomatous aspect 
with disruption of normal architecture of the organ.1,29 
In this case report, the lymph node involvement was 
detected by CT images and confirmed at autopsy. The 
histology was characterized by lymphocitary depletion, 
contrary to what has been described hitherto. This 
histological difference may be explained by the chronic 
use of corticosteroid and other immunosuppressant 
drugs used in the past.
Hematologic abnormalities occur in up to 
50% of cases,25 and are characterized by marked 
leukocytosis (up to 50,000/mm3), eosinophilia (30% 
of cases), monocytosis, and lymphopenia. Atypical 
lymphocytes are not rare, usually appearing in the 
onset of symptoms,1,29 which is different from the 
and certain human leukocyte antigen (HLA) alleles 
were shown to be closely associated with cutaneous 
reactions).1,5,13 Reactivation of HHV-6 or other herpes 
virus can be evidenced by increases in the title of 
IgG anti HHV-6 after the second week of the rash 
onset by the maintenance of elevated IgM levels 
during the course of reaction14 or by detection of 
viral genome by protein chain reaction (PCR) in the 
blood. The latter, when absent, raises the suspicion 
of other sites for the viral reactivation, such as the 
spleen or lymph nodes.11,15 The role of herpesvirus 
reactivation in the syndrome seems to be related to 
an immune response elicited by the drug, activating 
macrophages, lymphocytes, and cytokine release. The 
virus, housed in these cells, would therefore be jointly 
reactivated.16 Shiohara et al. proposed that the clinical 
symptoms during DIHS/DRESS do not only seem to 
be mediated by the expansion of drug-specific T cells, 
but also by antiviral T cells cross-reacting with drugs.1,16 
Depending on the extent of macrophage activation 
and the cytokine storm, a hemophagocytic syndrome 
may be elicited. In this case, hyperferritinemia may 
reflect this hypercytokinemia.17 In this case report, 
viral serologic work-up was undertaken precociously, 
at the beginning of the syndrome. These serologies 
could not be repeated because of the unfavorable 
outcome; therefore it was not possible to demonstrate 
the viral reactivation.
A recent review of literature concerning drugs 
related to DIHS/DRESS found 44 different drugs related 
to 172 cases in the period from 1997 until 2009.18 The 
most common drugs involved in the pathogenesis of 
DIHS/DRESS are the aromatic anticonvulsants (almost 
30% of the cases) such as phenytoin, carbamazepine, 
phenobarbital, lamotrigine, and primidone. However, 
other drugs are also well established as potential 
triggers, such as allopurinol, minocycline, calcium 
channel blockers, angiotensin converting enzymes 
inhibitors, beta-blockers, dapsone, terbinafine, 
NSAIDs, anti-retroviral drugs, quinine,19 sulfasalazine,20 
bupropion,21 ranitidine, methimazole, propylthiouracil, 
azathioprine, and biologic agents.1,22 Antibiotics are 
being fully associated with DIHS/DRESS, after recent 
reports where they were involved in 20% of cases.5 
Among them are trimethoprin-sulfamethoxazole, 
β-lactams, quinolones, and sulfonamide.1,3,5,11 In 
the case reported here, we observed the full clinical 
picture described for DIHS, precociously raising the 
suspicion. The latency period between the initial 
symptoms and the drugs’ exposure was 2 weeks, in 
accordance to the diagnostic requirements. In this 
case, it became difficult to confidently identify the 
culprit drug due to the presence of multiple drugs. 
Even so, we raised the suspicion that ciprofloxacin 
was the most probably offending drug, once this drug 
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abnormalities, conduction delay, sinus tachycardia, and 
ventricular arrhythmias. The echocardiogram may show 
systolic dysfunction and occasional pericardial effusion. 
Myocardial necrosis biomarkers may show elevation 
of creatine kinase-MB fraction and in severe cases of 
eosinophilic myocarditis troponin-I may also be raised. 
Sudden cardiac death has been reported.3,30,33,34 In this 
case report, the autopsy findings represented by the 
yellowish nodules and the histologic demonstration of 
myocardiocyte injury were interpreted as a myocardial 
lesion of the DIHS/DRESS syndrome.
Pancreatitis occurring in association with 
DIHS/DRESS is rare; generally it occurs as a late 
consequence of multiorgan failure.29 Roquin et al. 
reported a case of pancreatitis associated with 
DIHS/DRESS in the early stage of the disease. Criado 
et al, reported another case of a young woman who 
developed DHIS/DRES after using carbamazepin, 
presenting acute pancreatitis with a fatal outcome.35 
In the case reported here the elevation of lipase 
and amylase serum determinations were present 
at admission. The abdominal CT images did not 
elucidate a pancreatitis diagnosis, but the autopsy 
findings were indisputable.
Diagnosis of the syndrome is sometimes 
challenging due to incomplete clinical presentation. 
Therefore Bocquet et al. first proposed diagnostic 
criteria,29 requiring eosinophilia and/or lymphocytic 
atypia for the diagnosis. In the cases where this 
criterion was not present, like DIHS, diagnosis could not 
be considered definite or typical. Hence, the Japanese 
study group (SCR-J) adopted other criteria in which 
eosinophilia was not a mandatory criterion, but the 
HHV-6 replication requirement became an obstacle 
for its wide use. The European group, RegiSCAR, 
more recently proposed a third diagnostic criteria 
published by Kardaun et al., best suiting up the different 
institutions and the needs for diagnosis.36 Our case 
meets the diagnostic criteria for the SCR-J as atypical 
DIHS because of the lack of demonstration of HHV-6 
reactivation (for the reasons we discussed above). The 
RegiSCAR score of this case report was 5, namely: 
fever = 0/lymphadenomegaly = 1/skin rash extent 
suggesting DRESS = 2/organ involvement = 2 (liver, 
heart, pancreas). Unfortunately the criterion “other 
potential causes” could not be filled because of the 
lack of ANA testing. ANA was not tested because the 
patient had a history of rheumatoid arthritis and its 
positivity could be misinterpreted. Despite the abnormal 
renal function shown in Table 1, we did not consider 
the kidney in the list of involved organs because of the 
lack of microscopic findings at autopsy. Regardless 
eosinophilia that is observed 1-2 weeks later.30 
More rarely, thrombocytopenia, leukopenia, or even 
pancytopenia may be observed.5 Hemophagocytic 
syndrome has been reported in the course of DIHS/
DRESS, usually after the second week of the drug 
eruption.
After lymphadenopathy, the most common 
visceral involvement refers to the liver (50-60% 
of patients).25 More commonly, hepatic injury 
is represented by isolated elevation of hepatic 
transaminases, which is usually anicteric.1,29 Severe 
cases may present focal or spread hepatic necrosis, 
characterized by alanine transaminase (ALT) elevation 
of 10 times the reference value or by acute liver 
failure with coagulopathy and encephalopathy. This 
worse outcome is mostly observed in women in the 
fourth decade of life. Apparently it does not show a 
change in course with immunosuppressants. About 
15% of cases result in death or liver transplantation.1,30 
Splenomegaly is frequently observed accompanying 
hepatomegaly.30 The patient of this case report was 
a middle-aged woman who, after an initial apparent 
clinical improvement, developed a dramatic hepatic 
failure rapidly evolving to death. Splenomegaly 
was also present in this case. The autopsy found a 
submassive hepatic necrosis.
The renal involvement occurs in approximately 
11-15.8% of the cases,5,25 which is outlined by an 
increase in serum urea and creatinine, and sometimes 
by hematuria proteinuria or eosinophiluria.5,30 The 
kidney histology generally reveals tubulointerstitial 
nephritis and granulomatous necrotizing angiitis.6,31 
On admission laboratory tests, the patient of this 
report showed results being compatible with acute 
renal failure and an unquantified proteinuria on the 
urinalysis. The renal histology of the case reported 
here, was more compatible with a final event (acute 
tubular necrosis), but we assume the initial renal 
impairment, as due to DIHS/DRESS, once there was 
no other reason for the renal insufficiency.
Myocardial involvement is fairly variable, 
ranging between asymptomatic cases and heart 
failure, chest pain, dyspnea, and hypotension. The 
most severe presentation is represented by the acute 
necrotizing eosinophilic cardiogenic shock, implicated 
with drug hypersensitivity, which histology shows 
eosinophilic and lymphocytic infiltration with extensive 
myocardial cell necrosis.32 When symptomatic, the 
echocardiogram may show reduced left ventricular 
ejection fraction, and the chest x-ray shows an 
enlarged cardiac silhouette. The electrocardiogram is 
nonspecific with changes in the ST segment or T wave 
12
Autopsy and Case Reports 2012; 2(4): 5-14 Campos FPF, Lima PP, Maragno L, Watanabe FT.
3. BourgeoisGP, Cafardi JA, Groysman V, Hughey LC. A 
review of DRESS-associated myocarditis. J Am Acad 
Dermatol. 2012;66:e229-36. http://dx.doi.org/10.1016/j.
jaad.2010.11.057
4. Tohyama M, Hashimoto K. New aspects of drug-induced 
hypersensitivity syndrome. J Dermatol. 2011;38:222–8. 
http://dx.doi.org/10.1111/j.1346-8138.2010.01176.x
5. Um SJ, Lee SK, Kim YH, et al. Clinical features of drug-
induced hypersensitivity syndrome in 38 Patients. J Investig 
Allergol Clin Immunol. 2010;20:556-62. PMid:21313995.
6. Ang C-C, Wang Y-S, Yoosuff E-LM, Tay Y-K. Retrospective 
analysis of drug-induced hypersensitivity syndrome: A 
study of 27 patients. J Am Acad Dermatol. 2010;63:219-27. 
PMid:20605253. http://dx.doi.org/10.1016/j.jaad.2009.08.050
7. Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report 
of a case of hepatitis with jaundice, pyrexia and exfoliative 
dermatitis. N Engl J Med. 1950;242:897-8. PMid:15416921. 
http://dx.doi.org/10.1056/NEJM195006082422304
8. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity 
syndrome. In v i t ro assesment of  r isk.  J  Cl in 
Invest. 1988;82:1826-32. PMid:3198757 PMCid:442760. 
http://dx.doi.org/10.1172/JCI113798
9. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month 
prospective survey of cutaneous drug reactions in a hospital 
setting. Br J Dermatol. 2003;149:1018-22. http://dx.doi.
org/10.1111/j.1365-2133.2003.05584.x
10. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity 
syndrome. Arch Intern Med. 1995;155:2285-90. http://dx.doi.
org/10.1001/archinte.1995.00430210033005
11. Gentile I, Talamo M, Borgia G. Is the drug-induced 
hypersensitivity syndrome(DHIS) due to human herpesvirus 6 
infection or to allergy-mediated viral reactivation? Report of 
a case and review of literature. BMC Infect Dis. 2010;10:49. 
Doi: 10.1186/1471-2334-10-49. http://dx.doi.org/10.1186/1471-
2334-10-49
12. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg 
SP. Familial occurrence of hypersensitivity to phenytoin. 
Am J Med. 1991;91:631-4. http://dx.doi.org/10.1016/0002-
9343(91)90216-K
13. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant 
hypersensitivity syndrome: implications for pharmaceutical 
care. Pharmacotherapy. 2007;27:1425-39. PMid:17896897. 
http://dx.doi.org/10.1592/phco.27.10.1425
14. Pritchett JC, Nanau RM, Neuman MG. The link between 
hypersensitivity syndrome reaction development and Human 
Herpes virus-6 reactivation. Int J Hepatol. 2012;2012:723062. 
http://dx.doi.org/10.1155/2012/723062
15. Shiohara T, Kano Y. A complex interaction between drug allergy 
and viral infection. Clin Rev Allerg Immunol. 2007;33:124-33. 
PMid:18094951. http://dx.doi.org/10.1007/s12016-007-8010-9
16. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity 
syndrome (DIHS): a reaction induced by a complex interplay 
of the number of involved organs, RegiSCAR criteria 
permit a maximum score of 2 for this item.
The exclusion of other serious infections, 
neoplastic diseases, autoimmune, or connective tissue 
diseases, is advisable for the accurate diagnosis 
DIHS/DRESS.1,11,37
Awareness, early recognition of the diagnosis 
of DIHS/DRESS and withdrawal of the offending 
drug are the most important steps toward clinical 
improvement.1,16 Systemic corticosteroids (prednisone 
or methylprednisolone) have been widely used in the 
treatment of the syndrome. The dose can be reduced 
after clinical and laboratory improvement, and slow-
tapered over 6-8 weeks afterwards, in order to prevent 
recurrence.1,3,16 Intravenous immunoglobulin (IVIG), 
plasmapheresis, or a combination of these therapies 
can be used in the case of worsening symptoms.16,38,39 A 
consensus of experts on the therapeutic management 
of DIHS/DRESS was published in 2010.40
This case was treated with a systemic 
corticosteroid, which resulted in cutaneous 
improvement and apparent improvement of liver 
enzymes, total bilirubins, renal function, and pancreatic 
enzymes. Clinical worsening was sudden and 
overwhelming, giving no chance for other therapeutic 
options.
CONCLUSION
This case report illustrates the potential severity 
of DIHS/DRESS, even in cases where control of the 
disease is supposedly achieved. We call attention to 
the diagnosis recognition and awareness of a possible 
fatal outcome.
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